Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

NeuroOne Reports Three Successful Large-Animal StereoCED Procedures

Neutral Impact 3 of 5 product/contract Written later

NeuroOne Medical Technologies announced that three large-animal procedures using its StereoCED platform were completed at the University of Minnesota as part of a preclinical epilepsy research program. The company says the procedures established technical feasibility, and it expects to recognize related animal-use revenue in fiscal Q4 2026 and plans a launch for human investigational studies later this quarter, though the filing gives no revenue amount and the platform is not approved for commercial use.

Key points

  • Three large-animal procedures completed at the University of Minnesota, announced August 27, 2026
  • In two of the three procedures, drug delivery electrodes delivered a study agent into targeted brain tissue and recorded electrophysiological activity from the same regions
  • Revenue from the animal-use devices is expected to be recognized in fiscal Q4 2026; no dollar amount is given
  • Human investigational device release is planned by the end of fiscal Q4 2026, with launch planned later this quarter

The filing

CompanyNEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Form8-K, current report
Filed with the SECAug 27, 2026, 9:05 AM ET
Accession number0001213900-26-094174

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.